Circulating cell-free DNA (cfDNA) was found in increased amounts in cancer patients and tumor-associated molecular alteration can be detected in cancer patient's samples. For this reason, the cfDNA analysis is actually considered as a new concept of liquid biopsy. We evaluated the presence and integrity of plasma cfDNA by ALU-based qPCR and the methylation profile of OSMR and SFRP1 genes promoter in a large cohort of colorectal cancer (CRC) patients (n 5 114) in comparison to healthy subjects (n 5 56) and patients with adenomatous lesions (n 5 22). Moreover, we studied the prognosis value focusing on histopathological staging and survival. The cfDNA concentration and the integrity index were increased in CRC patients. The ALU83 and ALU244 fragment dosage showed a moderate discriminant capacity between CRC patients and controls and CRC and adenoma patients. Especially, cfDNA was significantly higher in CRC patients at advanced histopathological stage. In addition, the increased cfDNA level was associated with poor prognosis. A comparison of methylation profile in matched tissue and plasma on 25 CRC patients was performed and only three mismatched cases were observed. A lower methylation quantification was observed in cfDNA than tissue DNA. The cfDNA methylation frequency was statistically different in controls, adenoma and CRC patients and this frequency increased with the histopathological stage of tumor. The adenoma and CRC patients methylated cfDNA showed a higher quantity of ALU83 and ALU244. An integrated approach, combining the detection of ALU fragments and cancer type-specific epigenetic alteration, can improve diagnostic efficiency and better define the prognostic value for CRC disease.
Introduction
Colorectal cancer (CRC) is the second most commonly diagnosed cancer in the world and after lung cancer, it is the most common cause of cancer death in Europe. 1 Screening for CRC plays a key role in reduction of CRC-related mortality, and the observed decline in the incidence of CRC since the mid-1980s is a striking proof of this effect, along with changes in risk factors. CRC screening may be divided into two main categories: (i) biological sample-based tests, including fecal, blood and urine tests, as well as (ii) colon structure-based and imagebased tests, including flexible sigmoidoscopy, total colonoscopy, CT colonography and double-contrast barium enema. 2 The current limitations of CRC screening are: low sensitivity of occult blood analysis and invasivity of the endoscopic procedure. Colonoscopy represents the gold standard method for CRC detection and monitoring, but its usefulness as a screening tool is limited: the inability to detect lesions not actually reached by the endoscope, the cumulative risk of repeated screening colonoscopies and even more important, the low compliance of the population for this invasive procedure, are factors that have to be taken into account. 3 Fecal occult blood test (FOBT) is the most widely used screening test 4 and has shown robust evidence for effectiveness, but it has a lower sensitivity, ranging from 33% to 50% for CRC, 5 indeed, for positive individuals a follow-up with sigmoidoscopy or colonoscopy is typically required. 6 Serum Carcinoembryonic antigen (CEA) quantification, having the great advantage of being a non-invasive tool, shows a high specificity for discriminating occult colorectal cancers but a very low sensitivity across all studies. 7, 8 Thus,
CEA is not recommended for use as a CRC screening test. 9 Nevertheless, the elevated preoperative CEA levels are an important independent prognostic factor and, importantly, predict outcome in patients at stage II disease.
The ideal screening tool for CRC is far from being established, but it is possible to improve the diagnostic power of current clinical tests by implementing new biomarkers.
Several molecular alterations found in tumor cells, such as DNA mutations and DNA methylation, are reflected in cellfree circulating DNA (cfDNA) released from the tumor into the bloodstream, thereby making cfDNA an ideal candidate for the basis of a blood-based cancer diagnosis test.
Although little is known about its origin, form or rate of release, it is believed that cfDNA is a result of increased and abnormal activation of apoptotic pathways in cancerous lesions leading to DNA fragmentation. 11, 12 Several studies have assessed the usefulness of quantitative and qualitative tumor-specific alterations of cfDNA as diagnostic, prognostic and monitoring markers in cancer patients, 13, 14 introducing the new concept of liquid biopsy. These markers include quantification of total cfDNA, 15 cfDNA integrity, 16 detection of mutations, 17 abnormalities of microsatellite sequences 18 and methylation of specific genes. 19 In our study, we evaluated the presence and integrity of circulating cfDNA in a large cohort of CRC by ALU-based qPCR. Moreover, we analyzed the methylation profile of OSMR (Oncostatin M Receptor) and SFRP1 (Secreted Frizzled-related Protein 1) genes in plasma and their involvement in the colon cancer progression.
Our goal was to study a new non-invasive panel for early detection and progression evaluation of CRC through the circulating cfDNA analysis by the combination of quantification and methylation testing.
Materials and Methods

Patients selection
Samples were collected and stored by Tissue BioBanking of the First Surgical Clinic of the Department of Surgical, Oncological and Gastroenterological Science of University of Padua.
A hundred and fourteen patients with CRC, 22 patients with adenomatous polyp of size >1 cm histologically confirmed and 56 control individuals were enrolled into the study. Venous blood was drawn from the patients prior to surgery or any medical treatment. The control group consisted of individuals who underwent colonoscopy and were verified to be cancer-and polyp-free. Of 25 patients with CRC, the tumor tissue was also collected and frozen in liquid nitrogen.
The study was approved by the local Ethics Committee and written informed consent was obtained from each participant.
Association of the cfDNA quantification, integrity index and methylation profile with the clinical variables, including age and gender, tumor size and site, pTNM stage, differentiation, parietal diffusion, mitotic index, necrosis, lymphocytic infiltrate, vascular and perineural invasion or the tumor markers, were studied.
Sample processing
A total of 7 ml of peripheral blood samples were collected from control individuals and patients using BD VacutainerV R Blood Collection Tube (Becton Dickinson and Company, Franklin Lake, NJ) with K 3 EDTA. Within the same collecting day, plasma samples were prepared by centrifugation at 3,000 rpm for 10 min. The plasma aliquots were stored at 2808 C until further analysis.
Plasma cfDNA and tissue DNA isolation. The plasma cfDNA was purified from 500 ll of plasma with QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions; the only exception was the wash step with the buffer AW2 which was performed twice to remove inhibitors of the polymerase chain reaction (PCR). The sample was eluted in 80 ll of Elution Buffer and was stored at 2208 C.
After homogenization of the tumor biopsy, tissue DNA was isolated and purified with QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions and was stored at 2208 C.
Quantification and integrity of cfDNA
The plasma cfDNA was evaluated by ALU-based quantitative Real Time-PCR (qPCR) by amplification and quantification of two amplicons: one longer (ALU244) and one shorter (ALU83) which was designed inside the longer amplicon. The ALU244 and ALU83 supposedly represent the amount of the released DNA from non-apoptotic process and the total circulating cfDNA in plasma, respectively.
In brief, the two primer sets were: ALU83 forward 5 0 -CTGAGGTCAGGAGTTCGAGACC-3 0 and reverse 5 0 -CCAC GCCCGGCTAATTTT-3 0 ; ALU244 forward 5 0 -GCGGTGGCT CACGCCTGTAA-3 0 and reverse 5 0 -GGAGTGCAGTGGCGC GATCT-3 0 ; the ALU PROBE was 6FAM-CCTGGCCAACA TGGTGAAACCCC-MGB.
What's new?
Liquid biopsy of circulating cell-free DNA (cfDNA) is an emerging approach in cancer screening that can potentially facilitate the early detection of tumor-derived molecular alterations. In our study, designed to explore the utility of liquid biopsy in colorectal cancer (CRC) detection, cfDNA quantification was found to be sufficiently capable of differentiating CRC patients from healthy controls and from patients with adenomatous polyps. Moreover, among CRC patients, those with higher cfDNA levels experienced worse prognosis, suggesting that cfDNA dosage predicts survival. CRC detection through cfDNA quantification may be improved through the addition of methylation biomarkers.
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The reaction was performed in 20 ll reaction volume containing 1X Fluocycle TM II PCR Master Mix, for probe (Euroclone, Milan, Italy), 0.9 lM of each ALU244 primer, while 0.05 lM of ALU83 forward and 0.9 lM of ALU83 reverse primer, 0.25 lM of ALU PROBE and 1 ll of cfDNA sample. The thermal protocol consisted of an initial denaturation at 958 C for 5 min followed by 40 cycles of denaturation at 958 C for 15 seconds and annealing/extension at 628 C for 1 min in a 7500 Fast Real-Time PCR System instrument (Applied Biosystems, Milan, Italy).
A no template control was included as negative control. The cfDNA absolute quantification was determined by a standard curve using 10-fold dilution of genomic DNA from peripheral blood of a healthy subject and was expressed in ng/ml of plasma.
The cfDNA integrity index was calculated as the quantitative ratio of ALU244 to ALU83 (244/83).
Bisulfite modification and methylation-specific real-time PCR Forty microliters of plasma cfDNA and 20 ll of tissue DNA samples were modified with sodium bisulfite treatment by EpiTect Bisulfite Kit (Qiagen, Hilden, Germany) following the manufacturer's protocol. For cfDNA samples, we performed the protocol: Sodium Bisulfite Conversion of Unmethylated Cytosines in DNA from Low-Concentration Solutions. Purified modified DNA was eluted in 25 ll of Buffer EB and used directly for qPCR analysis.
Sodium bisulfite-treated DNA was analyzed by the MethyLight assay, 20 a fluorescence-based real-time PCR technology that requires no further manipulations after the PCR step.
In brief, three sets of primers and probe designed specifically for bisulfite-converted methylated DNA were used: two sets for the promoter locus of the OSMR and SFRP1 genes and one set for MYOD gene as control to normalize the amount of input DNA.
The OSMR forward primer was 5 0 -GTTCGCGGCGTGA GTATTTT-3 0 , the OSMR reverse primer was 5 0 -GAAAC TCGCCCGTCGAAA-3 0 and the OSMR probe was 6FAM-5 0 -CGTTTTGTCGTTGCGTCG-3 0 -MGB (amplicon size: 95 bp); the SFRP1 forward primer was 5 0 -TTTTCGCGTCGG TGACG-3 0 , the SFRP1 reverse primer was 5 0 -AATCAACTC CCGACGAAACG-3 0 and the SFRP1 probe was 6FAM-5 0 -CGTGGTAACGAGTGCG-3 0 -MGB (amplicon size: 58 bp); MYOD forward primer was 5 0 -TTTTAGTTAGAGTGTTGA GAGGATTGTGT-3 0 , the MYOD reverse primer was 5 0 -CAT ACCGACCACCCCCATAA-3 0 and the MYOD probe was 6FAM-5 0 -ATTGTAGATTTAGGAAGAGGTT-3 0 -MGB (amplicon size: 82 bp).
The reaction was performed in 20 ll reaction volume containing 1X TaqMan Universal PCR Master Mix No AmpErase UNG (Applied Biosystems, Milan, Italy), 0.9 lM of each primer, 0.25 lM of probe and 4 ll of modified DNA. The thermal protocol consisted of an initial denaturation at 958 C for 10 min followed by 40 cycles of denaturation at 958 C for 15 seconds and annealing/extension at 608 C for 1 min in a 7500 Fast Real-Time PCR System instrument (Applied Biosystems, Milan, Italy).
A standard curve was run in triplicate for each target gene using 1:10 serial dilutions of EpiTect Control DNA, methylated and bisulfite converted (Qiagen, Hilden, Germany) The methylated control DNA was also used as a calibrator (run in duplicate) for each run performed.
Negative controls (no template control and EpiTect Control DNA, unmethylated and bisulfite converted, Qiagen, Hilden, Germany) were also included in duplicate for each set of reactions.
The amount of methylated DNA at a specific locus was calculated by PMR (percentage of methylated reference) dividing the concentration of target GENE/MYOD ratio of a sample by the target GENE/MYOD ratio of positive control and multiplying by 100. 21 The target gene was considered methylated: (i) if the PMR was >0 for the cfDNA samples, (ii) if the PMR was >1 for the tissue DNA. 22 
Statistical analysis
The data were subjected to statistical analysis by SAS v9.1 (SAS Institute, Inc., Cary, NC). The continuous variables were evaluated by the Mann-Whitney U test for two independent samples or the Kruskal-Wallis test for multiple comparison. The receiver operating characteristic (ROC) curve was calculated to evaluate the diagnostic performance of cfDNA quantification and the area under the curve (AUC) was calculated to evaluate the accuracy of discrimination. The categorical variables were evaluated by v 2 or Fisher's exact test. The degree of agreement between tissue and plasma profile is quantified by Cohen's kappa. The Kaplan-Meier method was performed for survival analysis and the survival functions were compared by the log rank test. All the tests were two-sides and a p < 0.05 was considered statistically significant. The graphical plots were performed by GraphPad Prism v5.0 (GraphPad Software, Inc., La Jolla, CA).
Result
Patients' characteristics A total of 192 individuals was included in our study. Data obtained from plasma samples of 114 CRC patients (male/ female: 56/58) were compared to 22 patients with adenomatous pre-cancer lesion (male/female: 15/7) and 56 subjects (male/female: 36/20) which underwent colonoscopy and resulted negative as controls. For controls, adenoma and CRC patients, the median (Q1-Q3) of age was 66 (59-73), 65 (63-74) and 67 (61-73) years, respectively. Selected subjects did not differ statistically by age and gender as verified by independence v 2 and ANOVA (Analysis of Variance) tests (p > 0.05 for both). Tumor histopathological characteristics were summarized in Table 1 .
Quantification and integrity index of cfDNA
The plasma circulating cfDNA concentration was measured by ALU-based qPCR: the ALU83 quantification was used to evaluate the total cfDNA across the three study groups, while the ALU244 likely represent the circulating non-apoptotic DNA.
In controls, adenoma and CRC patients, the measured ALU83 and ALU244 quantities were statistically different (p < 0.0001). The median (Q1-Q3) of ALU83 level was 7.30 (4.25-15.28), 7.60 (4.44-14.48) and 17.58 (9.96-35.59 ) ng/ml, respectively, and this distribution showed the ALU83 concentration was higher in CRC patients than the non-cancer groups (controls and adenoma patients) (Fig. 1a) . In the same way, the ALU244 quantification was increased in CRC patients and the ALU244 median (Q1-Q3) level was 3.16 (1.57-6.94), 2.08 (0.91-4.82) and 7.56 (3.60-18.29) ng/ml, respectively (Fig. 1b) . The circulating cfDNA integrity index was significantly higher in CRC than adenoma patients (p 5 0.0039), but it was similar to controls (Fig. 1c) .
The ALU83 and ALU244 ROC curves showed moderate discriminating capacity between controls and CRC patients with the accuracy AUC 5 0.7105 and AUC 5 0.7205 (p < 0.0001 for both), respectively ( Supplementary Fig. S1A ). About the ability of discriminate adenoma to CRC patients, the ROC curves of ALU83 and ALU244 showed discrete AUC 5 0.7083 (p 5 0.0021) and AUC 5 0.7636 (p < 0.0001), respectively ( Supplementary Fig. S1B ).
Considering the CRC patients group divided in early (CRC-I and CRC-II, n 5 67) and advanced stage (CRC-III and CRC-IV, n 5 47), the ALU83 and ALU244 concentrations were significantly higher than controls and adenoma patients ( Supplementary Fig. S2A ). In particular, the median (Q1-Q3) of ALU83 and ALU244 level was 13.15 (7.54-23 .88) and 6.13 (2.99-10.98) ng/ml in early stage, and 24.98 (13.03-70.92) and 8.84 (3.94-34.75) ng/ml in advanced stage, respectively. The cfDNA integrity index of CRC at early stage was significantly higher than controls and adenoma patients, suggesting that the integrity index can be useful for early diagnosis of CRC. The ROC curves of ALU83, ALU244 and integrity index between early stage CRC, controls and adenoma patients showed a satisfactory discriminating capacity of each marker (Supplementary Fig. S2B ).
cfDNA distribution in CRC patients
To evaluate different amount of cfDNA in the cancer progression, a stage-based classification of CRC patients was performed and then analyzed. The ALU83 concentration was similar in CRC-I and CRC-II and was increased CRC-III and CRC-IV with the median (Q1-Q3) of 13.32 (7. (Fig. 1d) . About ALU244 dosage, the quantity was higher in CRC-IV and statistically significant than CRC-I (p 5 0.0015) and CRC-II (p 5 0.0284). The median (Q1-Q3) of ALU244 concentration was 4.28 ( (Fig. 1e) . The integrity index was similar across all the stage, but a decrease for CRC-IV was observed, due to a higher increase in ALU83 than ALU244 concentration (Fig. 1f) . 
Tumor Markers and Signatures
Evaluating the several histopathological characteristics of tumor, described in Table 1 , with cfDNA concentration, we observed a higher quantity of ALU244 in tumor with mitotic index <20 (p 5 0.0368) and a significantly difference of ALU244 level in the several diameter range of the tumor with p 5 0.0181. CEA level was found significantly lower in Table 2 . The methylation of OSMR and SFRP1 gene was revealed in plasma but not in tumor tissue in one and two cases respectively, but this mismatching was not observed considering the methylation status. In tumor tissue and plasma cfDNA, the median of OMSR-PMR was 32.68% (11.39-65.96%) and 0.20% (0-12.02%), while the median of SFRP1-PMR was 127.40% (54.54-157.60%) and 3.76% (0.67-29.80%), respectively ( Supplementary Fig. S3 ). In terms of tumor histopathological classification, the PMR median did not present statistically difference between CRC at early (CRC I-II) and advanced stage (CRC III-IV) both in tumor tissue and plasma.
Association between methylation profile, cfDNA concentration and integrity index A hundred and twenty-four out of 192 plasma samples were analyzed for methylation profile of OSMR and SFRP1 genes. The samples were grouped in 36 (29%) controls, 18 (15%) adenoma and 70 (56%) CRC patients, of which 11 (16%) at CRC-I, 15 (21%) at CRC-II, 29 (42%) at CRC-III and 15 (21%) samples at CRC-IV stage.
The methylation frequency for each gene and methylation status was summarized in Table 3 and we observed significant difference in the comparison of the controls, adenoma and CRC patients. The 24.2% (30/124) of the cfDNA samples showed positive methylation profile for both target genes. The cfDNA methylation profile of OSMR and SFRP1 gene, was observed in 31.5% (39/124) and 40.3% (50/124) of all samples and the 79.5% (31/39) and 88% (44/50) of these cases were CRC patients, respectively. Considering the methylation status, 47.6% (59/124) of the cfDNA samples were identified as methylated profile and 79.7% (47/59) of these cases were CRC patients. The unmethylated profile was shown in 80.6% (29/36) of controls, 72.2% (13/18) of adenoma patients and 32.9% (23/70) of CRC patients.
Regarding the stratification for tumor histopathological stage, a major frequency of unmethylated profile was observed in the cfDNA of CRC-I for OSMR and SFRP1 gene with 81.8% (9/11) and 63.6% (7/11), respectively. The switch of methylation trend was found out in cfDNA of CRC-II with 53.3% (8/15 samples with methylated profile) for SFRP1 gene, while we noticed only an increase in methylation profile by 40.0% (6/15 samples with methylated profile) for OSMR gene. Finally, the methylation status of CRC-II was positively present in the 60.0% (9/15) of samples. In cfDNA of CRC-IV, 100.0% (15/15) and 73.3% (11/15) of samples showed methylation of the SFRP1 and OSMR gene, respectively. The frequency analysis of OSMR, SFRP1 gene and 
methylation status for pTNM stages showed a significant difference with p < 0.05 for each one. In terms of quantitative evaluation, the median of PMR value was different in CRC patients than controls and adenoma patients (p 5 0.0006 and p < 0.0001 for OSMR and SFRP1 gene, respectively), which resulted to be unmethylated. Moreover, we observed the PMR significantly increased with the histopathological stage in CRC patients (p 5 0.0101 and p 5 0.0012 for OSMR and SFRP1 gene, respectively).
In the methylated cfDNA of adenoma and CRC plasma samples, the ALU83 and ALU244 concentration was significantly higher (p < 0.05 and p < 0.01, respectively) than the unmethylated cfDNA samples, but the integrity index was similar for all the study groups (Table 4 ). In particular, considering CRC grouping by pTNM stage, the ALU83 and ALU244 concentration was significantly different (p < 0.01 for both) between methylated and unmethylated cfDNA of CRC at an advanced stage, but not at an early one.
Evaluating the several tumor histopathological parameters of CRC patients and the methylation profile, the vascular invasion and the methylated status were significantly associated with p 5 0.0135.
Prognostic value and survival analysis
After a median of follow up to 52 months, we observed 6.3% (6/95) of local recurrence and 28% (28/100) of dying.
The disease-free survival (DFS) and overall survival (OS) did not show association with methylation status.
Otherwise, the cfDNA level was associated with a poor prognosis: the concentration of ALU83 and ALU244 was significantly higher in dying patients (p < 0.01 for both). Using the median level as cut-off, the ALU83 (HR: 3.49; 95% CI: 1.58-7.71; p 5 0.002) and ALU244 (HR: 2.70; 95% CI: 1.25-5.84; p 5 0.012) concentration was significantly associated with patients survival and the Kaplan-Meier analysis showed different survival curves (Fig. 2) with a p 5 0.001 for the ALU83 and p 5 0.009 for the ALU244. Moreover, the median of OS was significantly lower (about 1 year) for patients with ALU83 and ALU244 concentration higher than cut-off.
In CRC patients, high cfDNA level was also significantly associated with poor prognosis in multivariate analysis (ALU83: HR 5 2.71, 95% CI: 1.22-6.02, p 5 0.0145; ALU244: HR 5 2.40, 95% CI: 1.11-5.19, p 5 0.0264), after adjustment for stage of disease, suggesting that the cfDNA concentration effect was independent from tumor histopathological staging.
Discussion
Colorectal cancer screening is especially challenging for the diagnosis of pre-cancerous adenomatous polyps regarded as essential for prevention, and representing a more difficult diagnostic target.
Circulating cfDNA is also released by the tumor into the bloodstream, reflecting a wide range of molecular alterations found in the tumor cells, such as DNA mutations and DNA methylation, thereby making cfDNA an ideal candidate for a blood-based cancer diagnosis test. 23 The utility of cfDNA detection and quantification was demonstrated in other possible clinical applications and is a promising non-invasive prognostic, diagnostic and screening tool. [24] [25] [26] In our study, we investigated the possible role of cfDNA concentration and its specific epigenetic alterations as a tool for detecting early lesions and progressing of CRC disease by an ALU-based qPCR method that was previously successfully applied in the study of other solid tumors.
27-30
Our results showed that total cfDNA concentration, quantifying the ALU83, was about 2.5-fold higher in CRC patients than in healthy subjects and adenoma patients. Although our findings showed an overall inability of cfDNA to discriminate subjects with pre-cancer lesion at high risk to tumor develop from those without endoscopic lesions, we observed a satisfactory capability of the cfDNA concentration to predict CRC patients (AUC: 0.7105; 95% CI: 0.6260-0.7950). Quantity and pattern of cfDNA significantly differed between controls, adenomatous polyps and CRC patients, increasing with tumorigenesis and histopathological grade. A significant increase in about 2-fold of cfDNA concentration (both for ALU83 and ALU244) was interestingly observed already at early stage of CRC (CRC I-II). In particular, the ALU244 showed a lower concentration in the patients with adenoma than controls, thus the gain of the ALU244 level was of about 3-fold respect to early CRC patients. This increasing significant trend was also held for the integrity index, suggesting a its role for the early diagnosis. Moreover, considering the tumor evolving, the total cfDNA quantity showed significant difference between the CRC I-II to CRC III-IV (CRC at an advanced stage) of about 2-fold higher. So, in the near future, thanks to non-invasivity of liquid biopsy, there will be the possibility to compare serial samples from the same patient and generate a readout of CRC disease progression.
It is known that circulating cfDNA is present in the blood of all individuals, and it can be found increased in a variety of condition (i.e., exercise, 31 autoimmune and inflammatory diseases), but the origin of this circulating nucleic acid molecules is still unclear, although two main points of view are taken into account: passive releasing by cell death and active releasing by living cell.
The analysis of cfDNA may have the potential to complement the current parameter of the cancer disease evaluation. It is now widely accepted that a single biomarker cannot fully distinguish between controls and cancer patients. Consequently an approach based on different markers would be preferable to achieve a stronger predictive ability.
Thus, to improve the sensitivity of cfDNA dosage, we decided to study the circulating tumor cfDNA in two different ways: the integrity index and the methylation profile of two specific genes showing hypermethylation in CRC. The integrity index is defined as the ratio of longer fragments to shorter fragments assessed by PCR amplification, representing the necrosis and apoptosis process of cell death, respectively. The premise is that many cancer cells are resistant to apoptosis to escape from immune system, so the necrosis is probably the principal event to cancer cell death, thus releasing in blood circulation random, non-specific and incomplete truncated fragments of DNA.
Even though the integrity index was reported as a potential diagnostic tool to individuate cancer and other diseases, due of its high sensitivity, 16, 32 our findings showed a similar distribution of cfDNA integrity index between controls and CRC patients, but we observed a significant difference between adenoma and CRC patients (p < 0.01). Consequently, we analyzed the longer fragment (ALU244) distribution level into the three study groups and we observed the ALU244 quantity in CRC patients was about 2.5-fold higher than controls and more of 3.6-fold higher than adenoma patients. This permitted us to determine a significant discrete discriminant capacity between adenoma to CRC patients (AUC:0.7636; 95% CI: 0.6423-0.8848; p < 0.0001). 
Tumor Markers and Signatures
Fragment quantity and pattern of plasma cfDNA differed significantly between healthy subjects and patients with precancer lesions or cancer, and increasing with tumorigenesis and tumor staging. We analyzed the correlation between cfDNA and CEA, knowing that serum CEA is a widely used biomarker for the prognosis of CRC, and the results showed cfDNA can be an independent marker. To further demonstrate the prognostic value of cfDNA, an increase in ALU244 concentration was associated with lower cell proliferation rate and higher tumor mass size. Nevertheless, a correlation between an elevated plasma cfDNA concentration and poor survival was highlighted.
However, our findings were in accordance with some studies, [33] [34] [35] but in contrast to others reporting a decrease in cfDNA integrity in CRC patients. [36] [37] [38] [39] Discrepancies across various studies may be related to many factors, including the selection of subjects or pre-analytical and analytical procedures, such as serum or plasma sample, DNA isolation or the quantification method. These variables are critical and need to be standardized for inter-laboratory analysis and reporting. Nevertheless, elevated cfDNA levels can be detected in several other conditions in addition to those with cancer. 40 To individuate the peculiarity of tumor, we evaluated the methylation profile of two gene promoters that were revealed to be hypermethylated in colorectal cancer tissue: the Oncostatin M Receptor (OSMR) and Secreted Frizzled-related Protein 1 (SFRP1) gene. The first one encodes a member of the type I cytokine receptor family and transduces oncostatin M and interleukin 31 induced signalling events with pro-or anti-proliferative functions, contest-and cell type-dependent. However, the OSMR gene methylation frequency resulted in a range from 32% to 90% in CRC samples analyzed in several previous studies. [41] [42] [43] Interestingly, OSMR promoter hypermethylation was also identified in stool DNA from CRC patients. 44 The second one encodes a member of the SFRP family that contains a cysteine-rich domain homologous to the putative Wnt-binding site of Frizzled proteins and acts as a soluble modulators of Wnt signalling. Epigenetic silencing of SFRP genes leads to deregulated activation of the Wnt-pathway which is associated with colon cancer. 45 Several authors described the methylation frequency of SFRP1 between 83% and 95% in CRC samples. [46] [47] [48] [49] To date, many studies had reported aberrant methylation in tissue of colon cancer, while relatively few reports studied CRC plasma methylation biomarkers, e. g. APC and RASSF1,
50
BCAT1 and IKZF1, 51 AGBL4, FLI1, and TWIST1, 52 PCDH10,
53
THBD and C9orf50 54 and CDKN2A 55 genes, with exception of the aberrant methylation of SEPT9 gene. This biomarker is currently included in non-invasive commercial kit called Epi proColonV R by Epigenomics AG (Germany, Berlin), the first and only FDA-approved blood-based colorectal cancer screening test.
A critical comparison of target genes promoter methylation profile in matched tissue and cfDNA was assessed on 25 patients with CRC. Our finding showed tissue DNA methylation was found in 88% of the samples for OSMR gene and 92% for SFRP1 gene, which was similar to published results from other groups. For OSMR gene, the results obtained in matched plasma samples revealed low concordance (48%) and specificity (33%) compared to tumor-tissue analysis, while for SFRP1 gene the corresponding analysis revealed a higher concordance (80%) and specificity (50%). Considering the methylation status, evaluating the positive methylation of at least one target gene, we observed a further improving concordance degree (84%) and specificity (100%) in matched plasma and tissue samples.
In general, the lower PMR value detected in plasma samples (of about 160-and 34-fold change for OSMR and SFRP1 gene, respectively) compared to tumor tissue, may to be due to the DNA dilution effect in the blood circulation. Nevertheless, the OSMR and SFRP1-PMR trend observed in the CRC samples at different histopathological stage seemed to be preserved.
Our findings are reported in a qualitative, as either positive or negative for the presence of OSMR and SFRP1 methylated sequences, and quantitative approach as PMR value. The OSMR and SFRP1 methylation in cfDNA was significantly higher and frequent compared to both the adenoma and controls samples, and it was noticed in CRC at advanced stage. Moreover, an significant increase in ALU fragments level was observed in the positive methylated cfDNA samples, with exception of seven cfDNA samples of the control group, which were methylated for OSMR and/or SFRP1 gene promoter. This detected aberrant methylation in healthy subjects could be explained by dynamic nature of epigenetic event which occur with environmental factors and lifestyle as aging, 56 smoke 57 and diet. 58 Nevertheless, we observed positive methylation profile was associated with the presence of vascular invasion by tumor cells, suggesting a more aggressive tumor phenotype.
However, our results confirmed that methylation of OSMR and SFRP1 gene promoter is a common epigenetic event in colorectal cancer and that this specific aberration can be frequently found in the circulation. In this frame, methylation biomarkers offer an opportunity for the clinical application, although the detection of methylation profile in plasma cfDNA has rather low sensitivity, it presents excellent specificity.
In conclusion, an integrated approach that combines the detection of ALU fragments and cancer type-specific epigenetic events, can improve the diagnostic efficiency and better define the prognostic value for CRC. Furthermore, cfDNA from plasma may be a useful non-invasive source of tumor biomarkers. Despite extensive investigations, there are no currently approved applications for liquid biopsies in the clinical setting. Although further validation tests are necessary, our findings are obtained from a reasonable good number of cancer cases and controls, including also pre-cancer lesions at high risk to develop CRC. The integration of our results, in the overview of liquid biopsy application to oncological clinical management of colorectal cancer to improve the compliance of patients for diagnostic procedures, could give a important push to develop medical devices. The proposed analytical methods are simple, likely rapid and they can easily be suitable to commercial tools for routinely lab workflows. Nevertheless, recently published data demonstrate that ongoing research holds the considerable promise for the future to develop tumor cfDNA molecular assays.
